References
Gäckle HC, Lang GE, Freissler KA, Lang GK. Chorioretinopathia centralis serosa. Klinische, fluoreszeinangiographische und demographische Aspekte [Central serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspects]. Ophthalmologe. 1998;95(8):529-533. doi:10.1007/s003470050310.
Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc. 1986;84:799-845.
Iida T, Yannuzzi LA, Spaide RF, Borodoker N, Carvalho CA, Negrao S. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina. 2003;23(1):1-138. doi:10.1097/00006982-200302000-00001.
Liu B, Deng T, Zhang J. RISK FACTORS FOR CENTRAL SEROUS CHORIORETINOPATHY: A Systematic Review and Meta-Analysis. Retina. 2016;36(1):9-19. doi:10.1097/IAE.0000000000000837.
American Academy of Ophthalmology. 2020-2021 Basic and Clinical Science Course (BCSC), Complete Set. S.l.: Amer Academy of Ophthalmo; 2020.
Schachat AP, ed. Ryan’s Retina. Sixth edition. Edinburgh ; New York: Elsevier; 2018.
Salmon JF, Kanski JJ. Kanski’s Clinical Ophthalmology: A Systematic Approach. Ninth edition. Edinburgh: Elsevier; 2020.
Bhatti MT. 2020-2021 Basic and Clinical Science Course (BCSC), Section 05: Neuro-Ophthalmology. S.l.: Amer Academy of Ophthalmo; 2020.
Battaglia Parodi M, Arrigo A, Iacono P, Falcomatà B, Bandello F. Central Serous Chorioretinopathy: Treatment with Laser. Pharmaceuticals. 2020; 13(11):359.
van Rijssen TJ, van Dijk EHC, Yzer S, et al. Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73:100770.
Sartini, F., Figus, M., Nardi, M. et al. Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options. Eye 33, 1035–1043 (2019).
van Dijk EHC, Fauser S, Breukink MB, et al. Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial. Ophthalmology. 2018;125(10):1547-1555.